

## Product Information

# SILu™Prot VEGFA, Vascular Endothelial Growth Factor A, Human

Recombinant, Expressed in HEK cells, SIL MS Protein Standard,  $^{13}\text{C}$ - and  $^{15}\text{N}$ -Labeled

**MSST0005**

Storage Temperature  $-20\text{ }^{\circ}\text{C}$

Synonyms: VEGF-A, Vascular permeability factor (VPF)

## Product Description

SILu™Prot VEGFA is a recombinant, stable isotope-labeled human VEGFA which incorporates  $[^{13}\text{C}_6, ^{15}\text{N}_4]$ -Arginine and  $[^{13}\text{C}_6, ^{15}\text{N}_2]$ -Lysine. Expressed in human 293 cells, it is designed to be used as an internal standard for bioanalysis of VEGFA by mass spectrometry. It is a homodimer consisting of 165 amino acids (monomer) with a calculated molecular mass of 19.4 kDa. It contains no tags.

VEGFA belongs to the PDGF/VEGF growth factor family characterized by the presence of eight conserved cysteine residues and a cystine knot structure.<sup>1</sup> VEGF is secreted by the majority of tumor cells and initiates angiogenesis (formation of capillaries) by activating endothelial cells of existing blood vessels and promoting their migration.<sup>2</sup> VEGF has also been implicated in correlation with poor prognosis in breast cancer.<sup>2</sup> In addition, VEGF is released in rheumatoid arthritis in response to TNF- $\alpha$ , increasing endothelial permeability and stimulating angiogenesis.<sup>3,4</sup>

Each vial contains  $\geq 10.0\text{ }\mu\text{g}$  of SILu™Prot VEGFA standard, lyophilized from a solution of phosphate buffered saline. Vial content was determined by the Bradford method using BSA as a calibrator. The correction factor from the Bradford method to amino acid analysis is 110% for this protein.

### Identity

Confirmed by peptide mapping

### Purity

$\geq 95\%$  (SDS-PAGE)

### Heavy amino acid incorporation efficiency

$\geq 98\%$  (MS)

### UniProt

P15692-4

### Sequence Information

APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKAROLELNERTCRCDKPRR.

Transitions for three peptides (underlined) suggested for selected reaction monitoring analysis (SRM) are provided for download on the product display page at [www.sigmaaldrich.com](http://www.sigmaaldrich.com).

## Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Preparation Instructions

Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein in sterile ultrapure water to a final concentration of 100 µg/mL.

## Storage/Stability

Store the lyophilized product at –20 °C. The product is stable for at least 2 years as supplied. After reconstitution, it is recommended to store the protein in working aliquots at –20 °C.

## References

1. Robinson, C.J., and Stringer, S.E., The splice variants of vascular endothelial growth factor (VEGF) and their receptors. *J Cell Sci.*, 114, 853-865 (2001.)
2. Tang, X., Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. *Cancer Lett.*, 332, 3-10 (2013).
3. Ellis, L.M., Epidermal growth factor receptor in tumor angiogenesis. *Hematol. Oncol. Clin. North Am.*, 18, 1007-1021 (2004).
4. Afuwave, A.O. et. al., The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis.

## Legal Information

Sold under license from DuPont, U.S. Patent No. 7,396,688.

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party.

Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powder mill Rd.; Wilmington, DE 19803; 1-877-881- 9787 (voice), 1-302-695-1437 (fax), [licensing@dupont.com](mailto:licensing@dupont.com).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck, SRL and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2017-2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.  
23222510 Rev 05/25

